Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Acute myeloid leukemia stem cells elude the body's immune cells by deactivating a danger detector. The underlying mechanisms and the potential new therapeutic approaches that this gives rise to have been detailed in the journal Nature by researchers from the University of Basel and University Hospital Basel in collaboration with colleagues in Germany.
A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status.
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.
A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute "Cancer Moonshot" grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern.
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.
New findings about a fatal form of blood cancer could aid the development of new drugs with significantly less harmful side effects than existing chemotherapy.
Many individuals forced to fight an exceptionally aggressive form of the blood cancer acute myeloid leukemia (AML) don't survive more than five years.
11,000 people are predicted to die from acute myeloid leukemia in 2019, according to the American Cancer Society. The cancer starts in the bone marrow. There, mutated genes fail to prevent blood cells from replicating again and again and again, growing tumors.
Acute erythroid leukemia is a high-risk cancer with a dismal prognosis, uncertain genetic basis and controversy surrounding the diagnosis. That is changing, thanks to research led by St. Jude Children's Research Hospital that appears today in the journal Nature Genetics.
Chemistry researchers at Oregon State University have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
The prognosis for older patients with acute myeloid leukemia is poor: very few achieve remission and for those that don't the option is largely palliative.
Cancer cells consume sugar at a higher rate than healthy cells, but they're also hungry for amino acids, the building blocks of proteins and other biomolecules.
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry's first digital PCR products to receive U.S. Food and Drug Administration clearance.
Acute myeloid leukemia is the most common form of acute leukemia. It is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells.
In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.
Leukemia promotes premature aging in healthy bone marrow cells - according to new research from the University of East Anglia.
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.
The abnormal expression of different classes of molecules is known to be linked to various types of cells becoming cancerous.
A mechanism which drives leukemia cell growth has been discovered by researchers at the University of Sussex, who believe their findings could help to inform new strategies when it comes to treating cancer.